The study identifies the boundaries of the NS3 protease domain in HCV, providing a structural basis for the development of antiviral protease inhibitors.
Answers are grounded in this paper and cite their sources.
Defines HCV NS3 protease boundaries in vitro; leaves open whether these enable effective inhibitor development in humans.
NS3 of hepatitis C virus (HCV) is a serine protease that carries out the proteolytic processing of the nonstructural proteins of the HCV polyprotein. Deletion analysis of the N terminus of NS2,3,4 fusion protein revealed that the N-terminal boundary of the active protease resides between amino acids 1050 and 1083. The processing patterns of internal deletion mutants of NS2,3,4 indicated that the C terminus of the enzymically active protease resides between amino acids 1115 and 1218. The N- and C-terminal boundaries of the protease were also confirmed by determining the trans-cleavage activity of internally deleted NS3,4. NS3 protease activity was inhibited by Cu2+ but was slightly enhanced by Zn2+. This report provides a possible approach for development of antiviral agents based on protease inhibitors.
No takes yet. Share an insight, caveat, or question.
Han et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: